nodes	percent_of_prediction	percent_of_DWPC	metapath
Flavoxate—PDE7A—nervous system—Gilles de la Tourette syndrome	0.0487	0.0659	CbGeAlD
Flavoxate—PDE7A—central nervous system—Gilles de la Tourette syndrome	0.0469	0.0634	CbGeAlD
Flavoxate—PDE7B—nervous system—Gilles de la Tourette syndrome	0.0426	0.0576	CbGeAlD
Flavoxate—PDE8B—midbrain—Gilles de la Tourette syndrome	0.0412	0.0558	CbGeAlD
Flavoxate—PDE7B—central nervous system—Gilles de la Tourette syndrome	0.041	0.0554	CbGeAlD
Flavoxate—PDE4C—midbrain—Gilles de la Tourette syndrome	0.0382	0.0516	CbGeAlD
Flavoxate—PDE7A—brain—Gilles de la Tourette syndrome	0.0372	0.0503	CbGeAlD
Flavoxate—PDE8A—midbrain—Gilles de la Tourette syndrome	0.0371	0.0501	CbGeAlD
Flavoxate—PDE8B—nervous system—Gilles de la Tourette syndrome	0.0339	0.0458	CbGeAlD
Flavoxate—PDE8B—central nervous system—Gilles de la Tourette syndrome	0.0326	0.0441	CbGeAlD
Flavoxate—PDE7B—brain—Gilles de la Tourette syndrome	0.0326	0.044	CbGeAlD
Flavoxate—PDE4C—nervous system—Gilles de la Tourette syndrome	0.0314	0.0424	CbGeAlD
Flavoxate—PDE4C—central nervous system—Gilles de la Tourette syndrome	0.0302	0.0409	CbGeAlD
Flavoxate—PDE8B—brain—Gilles de la Tourette syndrome	0.0259	0.035	CbGeAlD
Flavoxate—PDE4C—brain—Gilles de la Tourette syndrome	0.024	0.0324	CbGeAlD
Flavoxate—PDE8A—brain—Gilles de la Tourette syndrome	0.0233	0.0315	CbGeAlD
Flavoxate—PDE4D—brain—Gilles de la Tourette syndrome	0.0211	0.0286	CbGeAlD
Flavoxate—PDE4A—brain—Gilles de la Tourette syndrome	0.0187	0.0253	CbGeAlD
Flavoxate—PDE4B—midbrain—Gilles de la Tourette syndrome	0.0177	0.024	CbGeAlD
Flavoxate—PDE4B—nervous system—Gilles de la Tourette syndrome	0.0146	0.0197	CbGeAlD
Flavoxate—CHRM2—nervous system—Gilles de la Tourette syndrome	0.0145	0.0196	CbGeAlD
Flavoxate—PDE4B—central nervous system—Gilles de la Tourette syndrome	0.014	0.019	CbGeAlD
Flavoxate—CHRM2—central nervous system—Gilles de la Tourette syndrome	0.0139	0.0189	CbGeAlD
Flavoxate—CHRM1—nervous system—Gilles de la Tourette syndrome	0.0132	0.0178	CbGeAlD
Flavoxate—CHRM1—central nervous system—Gilles de la Tourette syndrome	0.0127	0.0172	CbGeAlD
Flavoxate—PDE4B—brain—Gilles de la Tourette syndrome	0.0111	0.0151	CbGeAlD
Flavoxate—CHRM2—brain—Gilles de la Tourette syndrome	0.0111	0.015	CbGeAlD
Flavoxate—CHRM1—brain—Gilles de la Tourette syndrome	0.0101	0.0136	CbGeAlD
Flavoxate—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00729	0.028	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0072	0.0277	CbGpPWpGaD
Flavoxate—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00622	0.0239	CbGpPWpGaD
Flavoxate—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00614	0.0236	CbGpPWpGaD
Flavoxate—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00604	0.0232	CbGpPWpGaD
Flavoxate—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00596	0.0229	CbGpPWpGaD
Flavoxate—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00562	0.0216	CbGpPWpGaD
Flavoxate—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00555	0.0213	CbGpPWpGaD
Flavoxate—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00523	0.0201	CbGpPWpGaD
Flavoxate—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00516	0.0198	CbGpPWpGaD
Flavoxate—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00507	0.0195	CbGpPWpGaD
Flavoxate—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00501	0.0193	CbGpPWpGaD
Flavoxate—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00473	0.0182	CbGpPWpGaD
Flavoxate—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00467	0.0179	CbGpPWpGaD
Flavoxate—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00394	0.0151	CbGpPWpGaD
Flavoxate—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00389	0.0149	CbGpPWpGaD
Flavoxate—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00331	0.0127	CbGpPWpGaD
Flavoxate—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00327	0.0126	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00273	0.0105	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00265	0.0102	CbGpPWpGaD
Flavoxate—PDE8A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00249	0.00956	CbGpPWpGaD
Flavoxate—PDE8B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00249	0.00956	CbGpPWpGaD
Flavoxate—PDE8A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00242	0.00929	CbGpPWpGaD
Flavoxate—PDE8B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00242	0.00929	CbGpPWpGaD
Flavoxate—PDE8B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00226	0.00869	CbGpPWpGaD
Flavoxate—PDE8A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00226	0.00869	CbGpPWpGaD
Flavoxate—PDE8B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00225	0.00865	CbGpPWpGaD
Flavoxate—PDE8A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00225	0.00865	CbGpPWpGaD
Flavoxate—PDE7B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00222	0.00853	CbGpPWpGaD
Flavoxate—PDE8A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00219	0.00843	CbGpPWpGaD
Flavoxate—PDE8B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00219	0.00843	CbGpPWpGaD
Flavoxate—PDE7B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00215	0.00828	CbGpPWpGaD
Flavoxate—PDE7A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00206	0.00793	CbGpPWpGaD
Flavoxate—PDE8B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00204	0.00786	CbGpPWpGaD
Flavoxate—PDE8A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00204	0.00786	CbGpPWpGaD
Flavoxate—PDE7B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00201	0.00774	CbGpPWpGaD
Flavoxate—PDE7B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00201	0.00771	CbGpPWpGaD
Flavoxate—PDE7A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.002	0.00769	CbGpPWpGaD
Flavoxate—PDE7B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00195	0.00752	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00187	0.0072	CbGpPWpGaD
Flavoxate—PDE7A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00186	0.00717	CbGpPWpGaD
Flavoxate—PDE7B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00182	0.007	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00182	0.00699	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00173	0.00664	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00169	0.00651	CbGpPWpGaD
Flavoxate—PDE8B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00158	0.00606	CbGpPWpGaD
Flavoxate—PDE8A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00158	0.00606	CbGpPWpGaD
Flavoxate—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00147	0.00563	CbGpPWpGaD
Flavoxate—PDE8A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00143	0.0055	CbGpPWpGaD
Flavoxate—PDE8B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00143	0.0055	CbGpPWpGaD
Flavoxate—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00142	0.00547	CbGpPWpGaD
Flavoxate—PDE7B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.0014	0.0054	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00134	0.00516	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00133	0.00513	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00133	0.00513	CbGpPWpGaD
Flavoxate—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00133	0.00509	CbGpPWpGaD
Flavoxate—PDE7A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00131	0.00502	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.0013	0.00501	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.0013	0.00498	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.0013	0.00498	CbGpPWpGaD
Flavoxate—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00128	0.00491	CbGpPWpGaD
Flavoxate—PDE7B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00128	0.0049	CbGpPWpGaD
Flavoxate—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00124	0.00476	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00122	0.00469	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00122	0.00467	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00121	0.00464	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00121	0.00464	CbGpPWpGaD
Flavoxate—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0012	0.00461	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00119	0.00457	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00119	0.00456	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00118	0.00455	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00118	0.00455	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00117	0.0045	CbGpPWpGaD
Flavoxate—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00116	0.00448	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00115	0.00444	CbGpPWpGaD
Flavoxate—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00115	0.00444	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00115	0.00442	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00114	0.00436	CbGpPWpGaD
Flavoxate—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00112	0.00431	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00111	0.00428	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00111	0.00425	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.0011	0.00424	CbGpPWpGaD
Flavoxate—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00109	0.00417	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00108	0.00415	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00108	0.00414	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00107	0.00413	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00107	0.00412	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00106	0.00408	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00106	0.00407	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00103	0.00396	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00103	0.00396	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00103	0.00395	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00101	0.0039	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00101	0.00389	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00101	0.00387	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.001	0.00384	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.001	0.00384	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000998	0.00384	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000985	0.00379	CbGpPWpGaD
Flavoxate—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000983	0.00378	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000981	0.00377	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000961	0.00369	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000935	0.0036	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000932	0.00358	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00093	0.00357	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000918	0.00353	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000914	0.00351	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000908	0.00349	CbGpPWpGaD
Flavoxate—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000879	0.00338	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000851	0.00327	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000846	0.00325	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000845	0.00325	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000845	0.00325	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000783	0.00301	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000773	0.00297	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000773	0.00297	CbGpPWpGaD
Flavoxate—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00076	0.00292	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00076	0.00292	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000753	0.0029	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00075	0.00288	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00075	0.00288	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000741	0.00285	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000721	0.00277	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000708	0.00272	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000705	0.00271	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000701	0.00269	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.0007	0.00269	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000699	0.00269	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000673	0.00259	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000652	0.00251	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000652	0.00251	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000651	0.0025	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000643	0.00247	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00064	0.00246	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000627	0.00241	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000609	0.00234	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000597	0.0023	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000592	0.00228	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00058	0.00223	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000567	0.00218	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000553	0.00212	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00054	0.00208	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000536	0.00206	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.0005	0.00192	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000496	0.00191	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000489	0.00188	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000457	0.00175	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000442	0.0017	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000437	0.00168	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000429	0.00165	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000424	0.00163	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000402	0.00154	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.0004	0.00154	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000397	0.00153	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000397	0.00152	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000395	0.00152	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00039	0.0015	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000385	0.00148	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000378	0.00145	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000363	0.0014	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000359	0.00138	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00035	0.00135	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00028	0.00108	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000277	0.00106	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000254	0.000978	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000251	0.000966	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000237	0.000912	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000234	0.000901	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00023	0.000886	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000227	0.000874	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000215	0.000825	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000212	0.000815	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00015	0.000578	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000148	0.00057	CbGpPWpGaD
